Cargando…

The landscape of small nucleolar RNA expression in multiple myeloma is determined by cytogenetic alterations

Detalles Bibliográficos
Autores principales:	Zhao, Duoduo, Rohde, Christian, Göllner, Stefanie, Zhou, Fengbiao, Pauli, Cornelius, Blank, Maximilian Felix, Zinz, Rafael, Grab, Anna Luise, Poos, Alexandra M., John, Lukas, Huhn, Stefanie, Raab, Marc-Steffen, Müller-Tidow, Carsten, Weinhold, Niels
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10681893/ https://www.ncbi.nlm.nih.gov/pubmed/37845284 http://dx.doi.org/10.1038/s41375-023-02060-2

Ejemplares similares

P839: GAIN OF CHROMOSOME 1Q LEADS TO HIGH EXPRESSION OF SNORD78 AND ABERRANT RIBOSOME METHYLATION
por: Zhao, Duoduo, et al.
Publicado: (2023)

PB1976: CRISPR-CAS9 KNOCKOUT SCREEN IDENTIFIES RNA MODIFICATION ENZYMES ESSENTIAL FOR CELL SURVIVAL IN MULTIPLE MYELOMA
por: Zhao, D., et al.
Publicado: (2022)

NOP10 predicts lung cancer prognosis and its associated small nucleolar RNAs drive proliferation and migration
por: Cui, Chunhong, et al.
Publicado: (2020)

Protein tyrosine kinase 2b inhibition reverts niche-associated resistance to tyrosine kinase inhibitors in AML
por: Allert, Catana, et al.
Publicado: (2022)

Implications and prognostic impact of mass spectrometry in patients with newly-diagnosed multiple myeloma
por: Mai, Elias K., et al.
Publicado: (2023)

Therapeutic Advances Propelled by Deciphering Tumor Biology and Immunology—Highlights of the 8th Heidelberg Myeloma Workshop
por: Lutz, Raphael, et al.
Publicado: (2021)

The ribosomal protein S6 kinase alpha-1 (RPS6KA1) induces resistance to venetoclax/azacitidine in acute myeloid leukemia
por: Weidenauer, Katharina, et al.
Publicado: (2023)

Prevalence of the GFI1-36N SNP in Multiple Myeloma Patients and Its Impact on the Prognosis
por: Khandanpour, Cyrus, et al.
Publicado: (2021)

Integrated RNAi screening identifies the NEDDylation pathway as a synergistic partner of azacytidine in acute myeloid leukemia
por: Klosner, Justine, et al.
Publicado: (2021)

The Impact of Tumor Heterogeneity on Diagnostics and Novel Therapeutic Strategies in Multiple Myeloma
por: Rasche, Leo, et al.
Publicado: (2019)

Subclone-specific microenvironmental impact and drug response in refractory multiple myeloma revealed by single‐cell transcriptomics
por: Tirier, Stephan M., et al.
Publicado: (2021)

Nucleolar organiser regions in myeloma and benign paraproteinaemia.
por: Bryan, R. L., et al.
Publicado: (1990)

Investigation of Rare Non-Coding Variants in Familial Multiple Myeloma
por: Niazi, Yasmeen, et al.
Publicado: (2022)

Resolving the spatial architecture of myeloma and its microenvironment at the single-cell level
por: John, Lukas, et al.
Publicado: (2023)

Stem cell collection after lenalidomide, bortezomib and dexamethasone plus elotuzumab or isatuximab in newly diagnosed multiple myeloma patients: a single centre experience from the GMMG-HD6 and -HD7 trials
por: Kauer, Joseph, et al.
Publicado: (2023)

Longitudinal fluorescence in situ hybridization reveals cytogenetic evolution in myeloma relapsing after autologous transplantation
por: Merz, Maximilian, et al.
Publicado: (2017)

Characterizing the role of the immune microenvironment in multiple myeloma progression at a single-cell level
por: Schinke, Carolina, et al.
Publicado: (2022)

PB2081: CYTOGENETICS OF MULTIPLE MYELOMA IN MOROCCO
por: Moutmir, Yasmine, et al.
Publicado: (2023)

Characterization of rare germline variants in familial multiple myeloma
por: Catalano, Calogerina, et al.
Publicado: (2021)

Genome-wide interaction and pathway-based identification of key regulators in multiple myeloma
por: Chattopadhyay, Subhayan, et al.
Publicado: (2019)

P879: EXENT AND FLC MASS SPECTROMETRY FOR SEROLOGICAL IDENTIFICATION AND QUANTIFICATION OF MONOCLONAL IMMUNOGLOBULINS IN MULTIPLE MYELOMA
por: Huhn, S., et al.
Publicado: (2022)

Comparison of NGS and MFC Methods: Key Metrics in Multiple Myeloma MRD Assessment
por: Kriegsmann, Katharina, et al.
Publicado: (2020)

Interpretation of cytogenetic results in multiple myeloma for clinical practice
por: Rajan, A M, et al.
Publicado: (2015)

IgE type multiple myeloma exhibits hypermutated phenotype and tumor reactive T cells
por: Kehl, Niklas, et al.
Publicado: (2022)

Autologous Stem Cell Collection after Daratumumab, Bortezomib, Thalidomide, and Dexamethasone versus Bortezomib, Cyclophosphamide, and Dexamethasone in Newly Diagnosed Multiple Myeloma
por: Sauer, Sandra, et al.
Publicado: (2023)

An mTORC1 to HRI signaling axis promotes cytotoxicity of proteasome inhibitors in multiple myeloma
por: Darawshi, Odai, et al.
Publicado: (2022)

The Immune Microenvironment in Multiple Myeloma Progression at a Single-cell Level
por: Schinke, Carolina, et al.
Publicado: (2023)

Selective elimination of immunosuppressive T cells in patients with multiple myeloma
por: Awwad, Mohamed H. S., et al.
Publicado: (2021)

Conventional and Molecular Cytogenetic Analyses in Turkish Patients with Multiple Myeloma
por: Durak, Beyhan Aras, et al.
Publicado: (2012)

Occurrence and prognostic significance of cytogenetic evolution in patients with multiple myeloma
por: Binder, M, et al.
Publicado: (2016)

Clinicopathological Characteristics of Hyperdiploidy with High-Risk Cytogenetics in Multiple Myeloma
por: Yang, Naery, et al.
Publicado: (2018)

Cytogenetic and FISH analysis of 93 multiple myeloma Moroccan patients
por: Hamdaoui, Hasna, et al.
Publicado: (2020)

Multiple myeloma with high-risk cytogenetics and its treatment approach
por: Hanamura, Ichiro
Publicado: (2022)

Inhibiting PI3K–AKT–mTOR Signaling in Multiple Myeloma-Associated Mesenchymal Stem Cells Impedes the Proliferation of Multiple Myeloma Cells
por: Heinemann, Luca, et al.
Publicado: (2022)

ERG Transcriptional Networks in Primary Acute Leukemia Cells Implicate a Role for ERG in Deregulated Kinase Signaling
por: Bock, Juliane, et al.
Publicado: (2013)

P930: ISATUXIMAB, LENALIDOMIDE, BORTEZOMIB AND DEXAMETHASONE AS INDUCTION THERAPY FOR NEWLY-DIAGNOSED MULTIPLE MYELOMA PATIENTS WITH HIGH-RISK CYTOGENETICS: A SUBGROUP ANALYSIS FROM THE GMMG-HD7 TRIAL
por: Mai, E. K., et al.
Publicado: (2022)

Cytogenetic and interphase Fluorescence in Situ Hybridization studies in patients with multiple myeloma
por: Perumal, G, et al.
Publicado: (2014)

Relationship between initial clinical presentation and the molecular cytogenetic classification of myeloma
por: Greenberg, Alexandra J., et al.
Publicado: (2013)

Cytogenetic abnormality in patients with multiple myeloma analyzed by fluorescent in situ hybridization
por: Hu, Ying, et al.
Publicado: (2016)

Cytogenetic abnormalities in multiple myeloma: association with disease characteristics and treatment response
por: Abdallah, Nadine, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_12b57qi6dni2m8vt3cb56um22f